Disulfiram alleviates immune-mediated liver injury by inhibiting pyroptosis in hepatocytes through the NF-κB pathway

被引：0
作者：
Xiong, Wanyuan [1 ]
Li, Junfeng [1 ,2 ]
Mao, Xiaorong [3 ]
Qian, Zibing [1 ]
Tian, Aiping [3 ]
Peng, Xuebin [3 ]
Yang, Zhongxia [3 ]
Li, Haixia [1 ]
Li, Ziyi [1 ]
机构：
[1] Lanzhou Univ, Hosp 1, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China
[2] Lanzhou Univ, Hosp 1, Inst Infect Dis, Dept Hepatol, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
[3] Lanzhou Univ, Hosp 1, Dept Infect Dis, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
来源：
EUROPEAN JOURNAL OF PHARMACOLOGY | 2025年 / 992卷
基金：
中国国家自然科学基金;
关键词：
Disulfiram; Immune-mediated liver injury; ConA; Pyroptosis; Hepatocytes; NF-kappa B; ACTIVATION; FIBROSIS;
D O I：
10.1016/j.ejphar.2025.177352
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Immune-mediated liver injury (ILI) is a condition characterized by inflammation and cell death in the liver. Disulfiram, an FDA-approved drug for alcohol aversion, shows potential as a therapeutic agent in liver diseases, although its effects on immune liver injury remain unclear. This study aims to investigate the therapeutic effects of disulfiram using a mouse model of ILI induced by concanavalin A (ConA) and AML12 hepatocytes in vitro. Various techniques were employed, including Western blotting, qRT-PCR, cell viability assays, histopathological evaluations, immunohistochemistry, TUNEL staining, caspase-1 activity assays, cytokine detection, Cellular Thermal Shift Assay, and EdU proliferation assays. The results demonstrate that the ConA-induced ILI model exhibits significant liver damage and cellular pyroptosis, with disulfiram administered at specific concentrations markedly reducing the inflammatory response. Moreover, disulfiram attenuates pyroptosis in ConA-induced ILI and reduces cell injury in AML12 hepatocytes triggered by ConA and LPS + ATP, while facilitating post-injury cell proliferation. Mechanistically, the anti-pyroptosis effects of disulfiram are associated with the inhibition of the NF-kappa B signaling pathway in vitro. These results suggest that hepatocellular pyroptosis plays a pivotal role in the pathogenesis of ILI, and that disulfiram alleviates ILI symptoms by modulating the NLRP3/Caspase-1/ GSDMD-mediated classical pyroptosis pathway through the NF-kappa B signaling cascade. Subsequent investigations will explore the impact of disulfiram in diverse liver injury models and its synergistic effects with other drugs to improve therapeutic outcomes. Additionally, clinical trials are imperative to validate these findings in humans and establish disulfiram as a standard treatment for ILI, thereby paving the way for innovative therapeutic approaches.
引用
收藏
页数：15
相关论文
共 38 条
  • [1] Che Y., Chien Y., Zhu Y., Et al., GSDMD-dependent neutrophil extracellular traps mediate portal vein thrombosis and associated fibrosis in cirrhosis, Int. J. Mol. Sci., 25, (2024)
  • [2] Chen P., Zhou Y.K., Han C.S., Et al., Stem cells from human exfoliated deciduous teeth alleviate liver cirrhosis via inhibition of gasdermin D-executed hepatocyte pyroptosis, Front. Immunol., 13, (2022)
  • [3] Chen T.T., Li X.Q., Li N., Et al., β-arrestin2 deficiency ameliorates S-100-induced autoimmune hepatitis in mice by inhibiting infiltration of monocyte-derived macrophage and attenuating hepatocyte apoptosis, Acta Pharmacol. Sin., 44, pp. 2048-2064, (2023)
  • [4] Deng W., Yang Z., Yue H., Ou Y., Hu W., Sun P., Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation, Free Radic. Biol. Med., 152, pp. 8-17, (2020)
  • [5] Ding J., Wang K., Liu W., Et al., Pore-forming activity and structural autoinhibition of the gasdermin family, Nature, 535, pp. 111-116, (2016)
  • [6] Fink S.L., Cookson B.T., Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages, Cell. Microbiol., 8, pp. 1812-1825, (2006)
  • [7] Gautheron J., Gores G.J., Rodrigues C., Lytic cell death in metabolic liver disease, J. Hepatol., 73, pp. 394-408, (2020)
  • [8] Guo W., Chen S., Li C., Xu J., Wang L., Application of disulfiram and its metabolites in treatment of inflammatory disorders, Front. Pharmacol., 12, (2021)
  • [9] Hammerich L., Tacke F., Hepatic inflammatory responses in liver fibrosis, Nat. Rev. Gastroenterol. Hepatol., 20, pp. 633-646, (2023)
  • [10] Hassan I., Ebaid H., Alhazza I.M., Al-Tamimi J., Rady A.M., Disulfiram enhances the antineoplastic activity and sensitivity of murine hepatocellular carcinoma to 5-FU via redox management, Pharmaceuticals, 16, (2023)
1234